Alterations of hepatic lipid content following COVID-19 in persons with type 2 diabetes.

IF 3.7 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

BMJ Open Diabetes Research & Care Pub Date : 2025-02-18 DOI:10.1136/bmjdrc-2024-004727

Yuliya Kupriyanova, Iryna Yurchenko, Pavel Bobrov, Frederik Bartels, Stefan Wierichs, Marc Jonuscheit, Benedict Korzekwa, Katsiaryna Prystupa, Martin Schön, Dania Mendez, Sandra Trenkamp, Volker Burkart, Robert Wagner, Vera Schrauwen-Hinderling, Michael Roden

{"title":"Alterations of hepatic lipid content following COVID-19 in persons with type 2 diabetes.","authors":"Yuliya Kupriyanova, Iryna Yurchenko, Pavel Bobrov, Frederik Bartels, Stefan Wierichs, Marc Jonuscheit, Benedict Korzekwa, Katsiaryna Prystupa, Martin Schön, Dania Mendez, Sandra Trenkamp, Volker Burkart, Robert Wagner, Vera Schrauwen-Hinderling, Michael Roden","doi":"10.1136/bmjdrc-2024-004727","DOIUrl":null,"url":null,"abstract":"Introduction: The study aimed to assess the effect of COVID-19 on hepatic lipid (HL) content, fibrosis risk, and adiposity in persons with type 2 diabetes.Research design and methods: Participants with type 2 diabetes with a history of mild COVID-19 (n=15, age 58±12 years, body mass index 30.9±5.2 kg/m2) were examined before (baseline) and 1 year (12±2 months) after (follow-up) recovery from COVID-19. Investigations for changes in metabolic risk comprised clinical examination, fasting blood sampling and MR-based measurements. Potential changes were corrected with the time course of the respective parameters in a group of participants who did not contract COVID-19 over the same time course (n=14, 61±6 years, 30.0±4.6 kg/m2).Results: COVID-19 resulted in a relative increase in HL content of 56% (95% CI 18%, 106%; p=0.04) measured as proton density fat fraction (HL-PDFF), corrected for the time course in the absence of COVID-19. While no changes in hepatic stiffness and volume, intramyocellular lipids, whole-body, subcutaneous and visceral adipose tissue volumes as well as homeostatic model assessment of insulin resistance and beta-cell function were observed.Conclusions: History of COVID-19 in persons with type 2 diabetes is associated with higher HL-PDFF after 1 year following recovery from infection.Trial registration number: NCT01055093.","PeriodicalId":9151,"journal":{"name":"BMJ Open Diabetes Research & Care","volume":"13 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836859/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Diabetes Research & Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjdrc-2024-004727","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The study aimed to assess the effect of COVID-19 on hepatic lipid (HL) content, fibrosis risk, and adiposity in persons with type 2 diabetes.

Research design and methods: Participants with type 2 diabetes with a history of mild COVID-19 (n=15, age 58±12 years, body mass index 30.9±5.2 kg/m²) were examined before (baseline) and 1 year (12±2 months) after (follow-up) recovery from COVID-19. Investigations for changes in metabolic risk comprised clinical examination, fasting blood sampling and MR-based measurements. Potential changes were corrected with the time course of the respective parameters in a group of participants who did not contract COVID-19 over the same time course (n=14, 61±6 years, 30.0±4.6 kg/m²).

Results: COVID-19 resulted in a relative increase in HL content of 56% (95% CI 18%, 106%; p=0.04) measured as proton density fat fraction (HL-PDFF), corrected for the time course in the absence of COVID-19. While no changes in hepatic stiffness and volume, intramyocellular lipids, whole-body, subcutaneous and visceral adipose tissue volumes as well as homeostatic model assessment of insulin resistance and beta-cell function were observed.

Conclusions: History of COVID-19 in persons with type 2 diabetes is associated with higher HL-PDFF after 1 year following recovery from infection.

Trial registration number: NCT01055093.

查看原文本刊更多论文

2型糖尿病患者感染COVID-19后肝脏脂质含量的变化

本研究旨在评估COVID-19对2型糖尿病患者肝脂质（HL）含量、纤维化风险和肥胖的影响。研究设计和方法：研究对象为2型糖尿病患者，伴有轻度COVID-19病史（n=15，年龄58±12岁，体重指数30.9±5.2 kg/m2），分别在COVID-19恢复前（基线）和恢复后1年（12±2个月）进行检查。对代谢风险变化的调查包括临床检查、空腹血液采样和基于核磁共振的测量。在同一时间内未感染COVID-19的一组参与者（n=14, 61±6年，30.0±4.6 kg/m2）中，根据各自参数的时间过程对潜在变化进行校正。结果：COVID-19导致HL含量相对增加56% (95% CI 18%, 106%；p=0.04)，以质子密度脂肪分数（HL-PDFF）测量，在没有COVID-19的情况下进行时间过程校正。虽然肝脏硬度和体积没有变化，但观察到细胞内脂质、全身、皮下和内脏脂肪组织体积以及胰岛素抵抗和β细胞功能的稳态模型评估。结论：2型糖尿病患者的COVID-19病史与感染恢复1年后较高的HL-PDFF相关。试验注册号：NCT01055093。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMJ Open Diabetes Research & Care Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

9.30

自引率

2.40%

发文量

123

审稿时长

18 weeks

期刊介绍： BMJ Open Diabetes Research & Care is an open access journal committed to publishing high-quality, basic and clinical research articles regarding type 1 and type 2 diabetes, and associated complications. Only original content will be accepted, and submissions are subject to rigorous peer review to ensure the publication of high-quality — and evidence-based — original research articles.